NCT04358614View on ClinicalTrials.gov

Baricitinib Therapy in COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

April 5, 2020

Study Completion Date

April 7, 2020

Conditions
COVIDPneumonia
Interventions
DRUG

Baricitinib 4 MG Oral Tablet

Baricitinib+antiviral therapy administration for 2 weeks

Trial Locations (1)

59100

Fabrizio Cantini, Prato

All Listed Sponsors
lead

Fabrizio Cantini

OTHER

NCT04358614 - Baricitinib Therapy in COVID-19 | Biotech Hunter | Biotech Hunter